7832:TSEBandai Namco Holdings Inc. Analysis
Data as of 2026-06-18 - not real-time
NT$11.55
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Technical outlook: The stock is trading at 11.55 TWD, comfortably above the computed support of 10.80 but well below the resistance of 13.35. The 20‑day SMA (≈11.39) sits beneath both the 50‑day (≈12.41) and 200‑day (≈12.79) averages, confirming a bearish trend, while the RSI at 47 indicates a neutral momentum. A bullish MACD histogram (+0.07) offers a faint upside hint, yet volume is on a decreasing trajectory, raising concerns about liquidity.
Fundamental backdrop: Intelligene reports sharply declining revenue (‑55% YoY), negative operating margins (‑114%) and zero earnings, resulting in a price‑to‑book of 7.3 – far above the sector norm. Despite a sizable cash reserve (≈785 M TWD), operating cash flow is negative and debt‑to‑equity is high (≈4.9), underscoring balance‑sheet strain. The biotech sector adds a layer of regulatory and development risk, while the market’s “Extreme Greed” sentiment may be overstating near‑term upside.
Fundamental backdrop: Intelligene reports sharply declining revenue (‑55% YoY), negative operating margins (‑114%) and zero earnings, resulting in a price‑to‑book of 7.3 – far above the sector norm. Despite a sizable cash reserve (≈785 M TWD), operating cash flow is negative and debt‑to‑equity is high (≈4.9), underscoring balance‑sheet strain. The biotech sector adds a layer of regulatory and development risk, while the market’s “Extreme Greed” sentiment may be overstating near‑term upside.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Bearish SMA alignment and price below short‑term trend line
- Decreasing volume indicating weakening buying pressure
- Proximity to technical support with limited upside catalyst
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Substantial cash buffer offsetting negative operating cash flow
- High debt‑to‑equity ratio increasing balance‑sheet vulnerability
- Regulatory and clinical‑trial uncertainty typical of biotech
Long Term
> 3 yearsPositive
Model confidence: 4/10
Key Factors
- Potential upside from pre‑clinical RNA therapeutics pipeline
- Market sentiment skewed toward risk‑on (Extreme Greed index)
- Long‑run valuation could improve if clinical milestones are met
Key Metrics & Analysis
Financial Health
Revenue Growth-55.00%
ROE-18.77%
ROA-11.11%
Debt/Equity4.91
P/B Ratio7.3
Op. Cash FlowNT$-122465000
Free Cash FlowNT$-127909504
Industry P/E24.3
Technical Analysis
TrendBearish
RSI47.2
SupportNT$10.80
ResistanceNT$13.35
MA 20NT$11.39
MA 50NT$12.41
MA 200NT$12.79
MACDBullish
VolumeDecreasing
Fear & Greed Index88.5
Valuation
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.22
Volatility34.76%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.